Are you Dr. Bahceci?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 28 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
800 Howard Ave
Yale Physicians Building
New Haven, CT 06519Phone+1 203-785-2140Fax+1 203-785-6414
Summary
- Dr. Erkut Bahceci, MD is a hematologist in New Haven, Connecticut. He is currently licensed to practice medicine in Virginia.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Loyola University Medical Center/Trinity-Mercy ChicagoResidency, Internal Medicine, 1993 - 1996
Marmara Univ- Fac MedClass of 1990
Certifications & Licensure
VA State Medical License 2011 - 2026
Clinical Trials
Publications & Presentations
PubMed
- 29 citationsMolecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.Catherine C Smith, Mark J Levis, Alexander E Perl, Jason E Hill, Matt Rosales
Blood Advances. 2022-04-12 - 1 citationsCorrection to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.Angela Joubert James, Catherine C. Smith, Mark R. Litzow, Alexander E. Perl, Jessica K. Altman
Clinical Pharmacokinetics. 2021-07-23 - 1 citationsSafety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.Akira Ono, Haruyasu Murakami, Takashi Seto, Toshio Shimizu, Sawori Watanabe
Drugs in R&D. 2021-03-01
Press Mentions
BlueSphere Bio Appoints Erkut Bahceci, M.D., as Chief Medical OfficerJanuary 30th, 2023- BlueSphere Bio Announces IND Clearance of Its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia PatientsJune 18th, 2024
